MCL is a rare B-cell non-Hodgkin lymphoma, which can lead to immunosuppression.[12,13] BTKi have shown promising efficacy in the treatment of MCL.[2] BTK is one of the key enzymes of the B-cell receptor (BCR) pathway that affects the growth, proliferation, adhesion and survival of B cells. This evidence concerns the gene BTK and B-cell non-Hodgkin lymphoma.